Memorion

Donepezil Hydrochloride, the active ingredient in Memorion, is an acetylcholinesterase inhibitor presented as an oral dosage form for oral use. It treats mild to moderate Alzheimer’s disease and Parkinson’s disease dementia in adult patients. GNH USA supplies Memorion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Donepezil Hydrochloride is an acetylcholinesterase inhibitor indicated for cognitive impairment associated with neurodegenerative disorders. Alzheimer's disease (mild to moderate): improves cognition, memory and daily functioning. Parkinson's disease dementia: supports cognitive performance and behavioral stability. Dementia associated with Alzheimer's disease: helps maintain orientation and memory skills.

Adverse reactions may occur with any dosage form of Donepezil Hydrochloride.

Common Side Effects: - Nausea - Diarrhea - Insomnia - Muscle cramps

Serious or Rare Side Effects: - Bradycardia - Severe liver enzyme elevation - Syncope

Careful assessment and monitoring are recommended before and during therapy with Donepezil Hydrochloride. Cardiac assessment: evaluate patients with pre‑existing conduction disorders or bradyarrhythmias. Gastrointestinal monitoring: watch for severe nausea, vomiting or weight loss. Respiratory caution: use cautiously in patients with asthma or chronic obstructive pulmonary disease. Renal/hepatic function: consider dose adjustment in severe impairment. Pregnancy and lactation: safety not established; avoid unless clearly needed. Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Donepezil Hydrochloride may interact with several drug classes; monitoring and avoidance are advised where appropriate.

Major Interactions (Avoid): - Anticholinergic drugs: may diminish therapeutic effect. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase plasma concentrations. - Beta‑blockers: may exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - NSAIDs: raise risk of gastrointestinal bleeding. - Other anticholinergic agents (e.g., diphenhydramine): may counteract benefit. - Additional acetylcholinesterase inhibitors: additive cholinergic activity.